Top Achievements
Year in Review
With over 30+ pediatric subspecialities available through the Hackensack Meridian Children’s Health network, each subspecialty has experienced important news and updates throughout the year.
We asked each pediatric subspecialty to narrow down their successes and changes into one 2022 Top Achievement to highlight for this virtual Outcome Report as a reflection of the Hackensack Meridian Children’s Health brand.
KHCH: Our Division of Developmental Pediatrics has been involved in research with the Autism Program investigating the connection between low language scores on the Bayley Infant and Toddler Scale of Development and subsequent autism diagnosis. Under the Autism Medical Home Grant, IRB approved research was completed examining primary pediatrician knowledge.
JMSCH: The division welcomed three new board certified Pediatric Hospital Medicine faculty who bring expertise in quality, safety and improvement science and participated in 4 national initiatives to improve care to hospitalized children.
The combined JMSCH and KHCH Pediatric Nephrology program was ranked in the top 50 in the nation by U.S. New & World Report, reflecting the clinical and academic strengths and national reputation of the division faculty and high quality care delivered to patients with complex renal disease, including dialysis and renal transplantation.
KHCH: This year, Guillermo Hidalgo, M.D. was the lead doctor for the first hands-on workshop on Acute Peritoneal Dialysis Catheter placement in Bogotá, Colombia. This workshop was a part of the Saving Young Lives initiative with the International Society of Nephrology. This workshop's goal aims for the prevention and management of acute kidney injury program implementation in low resources countries.
JMSCH: As one of the leading centers for pediatric kidney disease in the nation, our team is proud to be among a small number of centers in the world that are offering four international, multicenter trials researching the treatment of rare kidney diseases.
- VALIANT trial. Joseph M. Sanzari Children’s Hospital is currently the only site in New Jersey offering this study which aims to determine the effectiveness of a subcutaneously infused medication, pegcetacoplan, in inducing a remission in C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis. These diseases currently have no effective treatment.
- COMMUTE-p trial. This trial aims to study the effectiveness of crovalimab in the home treatment of pediatric patients with atypical hemolytic uremic syndrome.
- INShore trial. The goal of this trial is to study the efficacy, safety, and pharmacokinetics/pharmacodynamics of the intravenous medication obinutuzumab in inducing a long term remission in children and young adults aged 2-25 with frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS).
- VX-147 trial. This study will evaluate the safety, efficacy, tolerability, and pharmacokinetics of oral medication VX-147 with apolipoprotein L1 (APOL1)-associated proteinuric kidney disease. Pathogenic variants in the APOL1 gene are a major cause of the excess incidence of serious kidney disease in the African-American population.
JMSCH: The Joint Commission redesignated the joint Adult and Pediatric Advanced Palliative Care DSC. The Pain and Palliative care program now offers acupuncture as part of its integrative medicine program.
The Pediatric Urology team hosted the Second Annual Pediatric Urology Symposium In 2022. It was extremely successful, with over 150 virtual attendees. The symposium had faculty speakers from both of our hospitals.
The Pediatric Urology and Nephrology Clinic continued to grow this year as well.
JMSCH: With the addition of two pediatric urologists through our partnership with PUA, we have seen unprecedented growth in pediatric urology volume and procedures, Dr. Richard Schlussel served as the Trip Chief for a surgical mission in Guayacil, Ecuador at Hospital de Roberto Gilbert with Healing The Children. This thirty person team operated on approximately 40 patients with complex congenital pediatric urology conditions performing many involved reconstructions.